By Tapan Panchal

LONDON--Pharmaceutical company AstraZeneca PLC (AZN.LN) said Tuesday the U.S. Food and Drug Administration accepted a complete re-submission of a new drug application for a potential new medicine for treating high potassium levels in the human body.

The regulator accepted a new application for sodium zirconium cyclosilicate, or ZS-9, used for treating hyperkalaemia, it said. The new application was submitted by the company's unit ZS Pharma.

Write to Tapan Panchal at tapan.panchal@wsj.com

(END) Dow Jones Newswires

October 18, 2016 02:45 ET (06:45 GMT)

Copyright (c) 2016 Dow Jones & Company, Inc.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Astrazeneca Charts.
Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Astrazeneca Charts.